Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-30
2007-10-30
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S515000
Reexamination Certificate
active
10525439
ABSTRACT:
This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0] hexane's. The compounds of this invention are MUSCARINIC receptor antagonists which are useful, inter-ail for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through MUSCARINIC receptors. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through MUSCARINIC receptors.
REFERENCES:
patent: 3176019 (1965-03-01), Campbell et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5397800 (1995-03-01), Alker et al.
patent: 5735690 (1998-04-01), Malentacca
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 7049444 (2006-05-01), Banks et al.
patent: 0 325 571 (1989-07-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 413 455 (1991-02-01), None
patent: 0 801 067 (1997-10-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135989/1994 (1995-05-01), None
patent: WO91/09013 (1991-06-01), None
patent: WO93/16018 (1993-08-01), None
patent: WO93/16048 (1993-08-01), None
patent: WO95/15312 (1995-06-01), None
patent: WO95/15327 (1995-06-01), None
patent: WO96/33973 (1996-10-01), None
patent: WO97/36906 (1997-10-01), None
patent: WO97/45414 (1997-12-01), None
patent: WO98/05641 (1998-02-01), None
patent: WO98/29402 (1998-07-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Eglen et al., “Muscarinic receptor ligands and their therapeutic potential”,Current Opinion in Chemical Biology, 3:426-432 (1999).
Eglen et al., “Therapeutic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):409-414 (2001).
Felder et al., “Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Birdsall et al., “Muscarinic receptors: it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282.
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Sagara et al, “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45(4):984-987 (2002).
Mase et al., “Synthesis of a Muscarinic Receptor Antagonist via a Diastereoselective Michael Reaction, Selective Deoxyfluorination and Aromatic Metal-Halogen Exchange Reaction”,Journal of Organic Chemistry, 66(20):6775-6786 (2001).
Mitsuya et al., “Discovery of a Muscarinic M3Receptor Antagonist with High Selectivity for M3Over M2Receptors Among 2-[(1S,3S)-3-Sulfonylaminocyclopentyl]phenylacetamide Derivatives”Bioorganic&Medicinal Chemistry, 8:825-832 (2000).
Grover et al., “Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis”,Journal of Organic Chemistry, 65:6283-6287 (2000).
Moriya et al., “Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).
Jeppesen et al., “1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.02,6]heptanes as New Potent Muscarinic M1Agonists: Structure-Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives”,Journal of Medicinal Chemistry, 42(11):1999-2006 (1999).
Gupta Jang Bahadur
Mehta Anita
Anderson Rebecca
Deshmukh, Esq. Jayadeip R.
Heibel Esq. George E.
Nolan Jason M
Ranbaxy Laboratories Limited
LandOfFree
Fluoro and sulphonylamino containing 3,6-disubstituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluoro and sulphonylamino containing 3,6-disubstituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluoro and sulphonylamino containing 3,6-disubstituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835153